The CEO of Syntis Bio describes a novel obesity program that entered the clinic today and a broader platform that leverages the small intestine to impact metabolism and drug absorption
Rahul Dhanda describes the technology that Syntis uses to coat the upper region of the small intestine to modulate nutrient uptake, and the benefits this confers on metabolism and drug development.